Compare · BDX vs IRMD
BDX vs IRMD
Side-by-side comparison of Becton Dickinson and Company (BDX) and iRadimed Corporation (IRMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and IRMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.65B, about 35.0x IRMD ($1.19B).
- Over the past year, BDX is down 13.0% and IRMD is up 55.6% - IRMD leads by 68.6 points.
- BDX has been more active in the news (10 items in the past 4 weeks vs 5 for IRMD).
- BDX has more recent analyst coverage (25 ratings vs 1 for IRMD).
- Company
- Becton Dickinson and Company
- iRadimed Corporation
- Price
- $150.14-0.71%
- $94.37+0.32%
- Market cap
- $41.65B
- $1.19B
- 1M return
- -2.01%
- +8.62%
- 1Y return
- -12.95%
- +55.61%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 10
- 5
- Recent ratings
- 25
- 1
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
iRadimed Corporation
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest IRMD
- Director Scharen-Guivel Hilda Frederique sold $285,000 worth of shares (3,000 units at $95.00), decreasing direct ownership by 35% to 5,598 units (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $226,507 worth of shares (2,500 units at $90.60) as part of a pre-agreed trading plan (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $691,044 worth of shares (7,500 units at $92.14) as part of a pre-agreed trading plan (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $657,265 worth of shares (7,500 units at $87.64) as part of a pre-agreed trading plan (SEC Form 4)
- IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by iRadimed Corporation
- CEO, President, Chairman Susi Roger E. sold $631,341 worth of shares (7,500 units at $84.18) as part of a pre-agreed trading plan (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $642,862 worth of shares (7,500 units at $85.71) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by iRadimed Corporation
- iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits